angiotensin II receptor blockers, irbesartan
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2011 Mar 10;364(10):928-38 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation The Use of
angiotensin II receptor blockers, irbesartan
As Treatment, Chronic
Is equal Than
placebo
To reduce at 4 years cardiovascular events (stroke, myocardial infarction, or death): 5.4% per years in both groups. Neither it reduced AF recurrences in patients in sinus rhythm at baseline